Double blind randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis

British Medical Journal

Volumn 318, Issue 7190, 1999, Pages 1031-1035

  Evans, E Glyn V ^b   Sigurgeirsson, Bárdur ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ITRACONAZOLE; TERBINAFINE;

ADULT; AGED; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ONYCHOMYCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOE; UPPER RESPIRATORY TRACT INFECTION;

EID: 0033577556     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.318.7190.1031     Document Type: Article

References (15)

1. 1 Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992;126(suppl 39):23-7.
2. 2 Sais G, Jugglà A, Peyrí J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995;132:758-61.
3. 3 Editorial. Prevalence, morbidity and cost of dermatological diseases. J Invest Dermatal 1979;73:395-401.
4. 4 Heikkìlä H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995;133:699-703.
5. 5 de Backer M, de Keyser P, de Vroey C, Lesaffre E. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs itraconazole 200 mg/day - a double blind comparative trial. Br J Dermatol 1996;134(suppl 136):16-7.
6. 6 Bräutigam M, Nolting S, Schopf RE, Weidinger G for the Seventh Lamisil German Onychomycosis Study Group. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. BMJ 1995;311:919-21.
7. 7 Gupta AK, Scher RK. Oral antifungat agents for onychomycosis. Lancet 1998;351:541-2.
8. 8 André J, De Doncker P, Ginter G, Wang R, Stoffels P, Heremans A, et al. Intermittent pulse therapy with itraconazole in onychomycosis: an update [abstract]. 54th Annual Meeting, American Academy of Dermatology, Washington DC, 10-15 February 1996.
9. 9 Tosti A, Piraccini BM, Stinchi C. Treatment of dermatophyte nail infections: an open randomised study comparing intermittent terbinafine therapy with continuous terbinafine therapy and itraconazole therapy. J Am Acad Dermatol 1996;34:595-600.
10. 10 Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994;30:911-33.
11. 11 Elewski BE. Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the multicenter onychomycosis study of terbinafine. Arch Dermatol 1997;133:1317-8.
12. 12 Ellis DH, Marley JE, Watson AB, Williams TG. Significance of non-dermatophyte moulds and yeasts in onychomycosis. Br J Dermatol 1997;194(suppl 1):40-2.
13. 13 Clayton YM. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994;30(suppl 43):7-8.
14. 14 Schatz F, Braütigam M, Dobrowolski E, Effendy I, Haberl H, Mensing H, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995;20:377-83.
15. 15 De Doncker P, Decroix J, Piérard GE, Roelant D, Woestenborghs R, Jacqmin P, et al. Antifungal pulse therapy for onychomycosis: a pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996;132:34-41.